OptionalRegionHeading_Programs

EARLIER PUBLICATIONS

Guinan, P., Stewart, A.K., Fremgen, A. and Menck, H.R.: Patterns of care for metastatic carcinoma of the prostate gland: results of the American College of Surgeons' patient care evaluation study. In: Prostate Cancer and Prostatic Diseases. Stockton Press, pp 315-320, 1998.

Rubenstein, M., Mirochnik, Y., Guinan, P.: Delivery of biotinylated agents to prostate cancer cells utilizing hybrid monoclonal antibodies. In: Oligonucleotide & Gene Therapy-Based Antisense Therapeutics with New Applications for Genomics. W. Hori (ed) IBC Library Series, Southborough, MA, 1997, pp 4.2.1-4.2.10.

Rubenstein, M. and Guinan, P.: Inhibition of the autocrine loop regulated by the epidermal growth factor receptor (EGFR) and transforming growth factor-a (TGF-a) ligand. In: Emerging Therapeutic Targets. R. Anand, P. Smith and P. Warne (eds) Ashley Publications Ltd, London, 1997 pp 165-168.

Bridges, P., Sharifi, R., Razzaq, A. and Guinan, P.: Decreased survival of black Americans with testicular cancer. J. Urol. 159:1221-1223, 1998.

Chou, P.M., Barquin, N., Guinan, P., Sanz., C.R. and Gonzalez-Crussi, F.: Differential expression of p53, c-kit, and CD34 in prepubertal and postpubertal testicular germ cell tumors. Cancer 79:2430-2434, 1997.

DiDomenico, D., Guinan, P. and Sharifi, R.: Spontaneous expulsion of an intravesical bullet. JAOA 97:415-416, 1997.

DiDomenico, D., Bridges, P., Sharifi, R., Rubenstein, M., Guinan, P.: Survival of Mexican-American males with seminoma. Rev. Invest. Clin. 49:93-96, 1997.

Guinan, P., Shaw, M., Mirochnik, Y., Slobodskoy, L., Ray, V. and Rubenstein, M.: Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model. Meth. Find. Exp. Clin. Pharmacol. 20:739-742, 1998.

Guinan, P., Stuhldreher, D., Frank, W. and Rubenstein, M.: Report of 337 patients with renal cell carcinoma emphasizing 110 with stage IV disease and review of the literature. J. Surg. Oncol. 64:295-298, 1997.

Guinan, P., Imperato, J.P., Chmiel, J.S., Vogelzang, N.J. and Sylvester, J.: Cancer conferences. Can they be improved. Cancer Practice 5:305-308, 1997.

Guinan, P., Sobin, L.H., Algaba, F., Badellino, F., Kameyama, S., MacLennan, G. and Novick, A.: TNM staging of renal cell carcinoma. A Communication of the Union Internationale Contre le Cancer and the American Joint Committee on Cancer 992-993, 1997.

Guinan, P., DiDomenico, D., Brown, J., Shaw, M., Sharifi, R., Ray, V., Shott, S., Rubenstein, M. The Effect of Androgen Deprivation on Malignant and Benign Prostate Tissue. Med. Oncol. 14:145-152, 1997.

Lievano, G., DiDomenico, D., Brown, J., Bridges, P., Rubenstein, M., Shaw, M., Guinan, P.: Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-b1 in a rat orthotopic prostate adenocarcinoma. Meth. Find. Exp. Clin. Pharmacol. 19:261-267, 1997.

Lievano, G., Mirochnik, Y., Rubenstein, M., Shaw, M. and Guinan, P.: Antitumor effect of CPT-11, a new derivative of Camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo. Meth. Find. Exp. Clin. Pharmacol. 18:659-662, 1996.

Rubenstein, M., Glick, R., Lichtor, T., Mirochnik, Y., Chou, P. and Guinan, P.: Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-a and the epidermal growth factor receptor. Med. Oncol. 18:121-130, 2001.

Rubenstein, M., Mirochnik, Y., Slobodskoy, L. and Guinan, P.: Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell lines. Methods. Find. Clin. Pharmacol. 23:487-490, 2001.

Rubenstein, M. and Guinan, P.: A review of various antisense oligonucleotide therapeutic approaches for prostate cancer. The Prostate Journal 2:179-188, 2000.

Rubenstein, M., Shaw, M., Mirochnik, Y., Slobodskoy, L., Glick, R., Lichtor, T., Chou, P. and Guinan, P.: In vivo establishment of T98G human glioblastoma. Methods Find. Exp. Clin. Pharmacol. 21:391-393, 1999.

Rubenstein, M., Mirochnik, Y., Chou, P. and Guinan, P.: Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides. Meth. Find. Clin. Pharmacol. 20:825-831, 1998.

Rubenstein, M., Chou, P., Mirochnik, Y., Guinan, P.: Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation. Med. Oncol. 14:23-29, 1997.

Rubenstein, M., Mirochnik, Y., Ray, V., Guinan, P.: Lack of toxicity associated with the systematic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors. Med. Oncol. 14:131-136, 1997.

Rubenstein, M., Mirochnik, Y., Chou, P. and Guinan, P.: Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J. Surg. Oncol. 62:194-200, 1996.

Saffrin, R., Chou, P., Ray, V., Shaw, M., Rubenstein, M. and Guinan, P.: Suramin as adjuvant therapy with radical prostatectomy. The Prostate 28:325-327, 1996.

Shaw, M., Elterman, L., Rubenstein, M., McKiel, C.F. and Guinan, P.: Changes in radical prostatectomy and radiation therapy rates for African-Americans and whites. J. Natl. Med. Assoc. 92:281-284, 2000.

Shaw, M., Ratanawong, S., Chou, P., Ray, V., Mirochnik, Y., Slobodskoy, L., Rubenstein, M. and Guinan, P.: Paclitaxel, bropirimine and linomide: Effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms. Methods Find. Exp. Clin. Pharmacol. 20:111-114, 1998.

Uzoaru, I., Rubenstein, M., Mirochnik, Y., Slobodskoy, L., Shaw, M. and Guinan, P.: An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J. Surg. Oncol. 67:33-37, 1998.